PharmaCyte Biotech Balance Sheet Health
Financial Health criteria checks 6/6
PharmaCyte Biotech has a total shareholder equity of $53.0M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $70.2M and $17.2M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$32.64m |
| Equity | US$53.04m |
| Total liabilities | US$17.15m |
| Total assets | US$70.19m |
Recent financial health updates
Recent updates
PharmaCyte Biotech (NASDAQ:PMCB) Is In A Strong Position To Grow Its Business
Mar 22
PharmaCyte Biotech says CEO to step down, announces strategic review of business
Oct 07PharmaCyte Biotech reaches agreement with Iroquois to include 2 board of directors
Aug 15Is This A Good Time To Invest In PharmaCyte?
Jan 07PharmaCyte Biotech: Buy The 'Dump'
Aug 21Financial Position Analysis
Short Term Liabilities: PMCB's short term assets ($32.9M) exceed its short term liabilities ($7.5M).
Long Term Liabilities: PMCB's short term assets ($32.9M) exceed its long term liabilities ($9.7M).
Debt to Equity History and Analysis
Debt Level: PMCB is debt free.
Reducing Debt: PMCB had no debt 5 years ago.
Debt Coverage: PMCB has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: PMCB has no debt, therefore coverage of interest payments is not a concern.